EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: A possible step in the transition to low-grade serous carcinoma cells?

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Cheng, Jung Chien ^a   Auersperg, Nelly ^a   Leung, Peter C K ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CADHERIN; CHROMONE DERIVATIVE; FLAVONOID; MORPHOLINE DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CELL IMMORTALIZATION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; LOW GRADE SEROUS CARCINOMA CELL; MALIGNANT TRANSFORMATION; OVARY CANCER; PROTEIN EXPRESSION; SEROUS BORDERLINE OVARIAN TUMOR CELL; TUMOR CELLS AND CELL LINES; UPREGULATION; BIOSYNTHESIS; CANCER INVASION; CELL MOTION; CYSTADENOCARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

GASTROPODA;

CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CHROMONES; CYSTADENOCARCINOMA, SEROUS; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLAVONOIDS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MORPHOLINES; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS;

EID: 84859138356     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034071     Document Type: Article

References (46)

1. Thiery JP, (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
2. Lee JM, Dedhar S, Kalluri R, Thompson EW, (2006) The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981.
3. Huber MA, Kraut N, Beug H, (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558.
4. Tse JC, Kalluri R, (2007) Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101: 816-829.
5. Hynes NE, Lane HA, (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
6. Barr S, Thomson S, Buck E, Russo S, Petti F, et al. (2008) Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis 25: 685-693.
7. Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, et al. (1996) The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 73: 301-306.
8. Niikura H, Sasano H, Sato S, Yajima A, (1997) Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol 16: 60-68.
9. Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S, et al. (2006) Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol 290: C1532-1542.
10. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, et al. (2009) Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 100: 134-144.
11. Darai E, Scoazec JY, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, et al. (1997) Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol 28: 922-928.
12. Veatch AL, Carson LF, Ramakrishnan S, (1994) Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer 58: 393-399.
13. Gershenson DM, Silva EG, Tortolero-Luna G, Levenback C, Morris M, et al. (1998) Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer 83: 2157-2163.
14. Steffensen KD, Waldstrom M, Andersen RF, Olsen DA, Jeppesen U, et al. (2008) Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. Int J Oncol 33: 195-204.
15. Woo MM, Salamanca CM, Miller M, Symowicz J, Leung PC, et al. (2008) Serous borderline ovarian tumors in long-term culture: phenotypic and genotypic distinction from invasive ovarian carcinomas. Int J Gynecol Cancer 18: 1234-1247.
16. Cheng JC, Auersperg N, Leung PC, (2011) Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin. Oncogene 30: 1020-1031.
17. Cheng JC, Auersperg N, Leung PC, (2011) Inhibition of p53 represses E-cadherin expression by increasing DNA methyltransferase-1 and promoter methylation in serous borderline ovarian tumor cells. Oncogene 30: 3930-3942.
18. Woo MM, Salamanca CM, Symowicz J, Stack MS, Miller DM, et al. (2008) SV40 early genes induce neoplastic properties in serous borderline ovarian tumor cells. Gynecol Oncol 111: 125-131.
19. Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, et al. (2005) Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 65: 1994-2000.
20. Woo MM, Salamanca CM, Minor A, Auersperg N, (2007) An improved assay to quantitate the invasiveness of cells in modified Boyden chambers. In Vitro Cell Dev Biol Anim 43: 7-9.
21. Carpenter G, (1987) Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56: 881-914.
22. Cheng JC, Klausen C, Leung PC, (2010) Hydrogen peroxide mediates EGF-induced down-regulation of E-cadherin expression via p38 MAPK and snail in human ovarian cancer cells. Mol Endocrinol 24: 1569-1580.
23. Ellerbroek SM, Halbleib JM, Benavidez M, Warmka JK, Wattenberg EV, et al. (2001) Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 61: 1855-1861.
24. Zhou HY, Pon YL, Wong AS, (2007) Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Endocrinology 148: 5195-5208.
25. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, et al. (2006) Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107: 1801-1811.
26. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A, (2004) Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 14: 1086-1096.
27. Ahuja D, Saenz-Robles MT, Pipas JM, (2005) SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24: 7729-7745.
28. Sablina AA, Hahn WC, (2008) SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev 27: 137-146.
29. Muller PA, Vousden KH, Norman JC, (2011) p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192: 209-218.
30. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, et al. (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091.
31. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
32. Farley J, Fuchiuji S, Darcy KM, Tian C, Hoskins WJ, et al. (2009) Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol Oncol 113: 341-347.
33. Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, et al. (1993) Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol 168: 162-169.
34. Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, et al. (1997) p53 and HER-2/neu overexpression in ovarian borderline tumors. Gynecol Oncol 65: 218-224.
35. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG, (2005) An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 29: 1034-1041.
36. Shih Ie M, Kurman RJ, (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164: 1511-1518.
37. Shih Ie M, Kurman RJ, (2005) Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 11: 7273-7279.
38. Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, et al. (1997) E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer 74: 275-280.
39. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC, (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22: 255-288.
40. Cho EY, Choi Y, Chae SW, Sohn JH, Ahn GH, (2006) Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int 56: 62-70.
41. Thiery JP, Sleeman JP, (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142.
42. Krall JA, Beyer EM, MacBeath G, (2011) High- and low-affinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways. PLoS One 6: e15945.
43. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, et al. (2010) Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett 291: 59-66.
44. Kuwabara Y, Yamada T, Yamazaki K, Du WL, Banno K, et al. (2008) Establishment of an ovarian metastasis model and possible involvement of E-cadherin down-regulation in the metastasis. Cancer Sci 99: 1933-1939.
45. Sayan AE, Griffiths TR, Pal R, Browne GJ, Ruddick A, et al. (2009) SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci U S A 106: 14884-14889.
46. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, et al. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939.